Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

amgen europe, b.v. - filgrastim - solução injetável - 48 m.u.i./0.5 ml - filgrastim 96 mu/ml - filgrastim - n/a - duração do tratamento: curta ou média duração

União Europeia - português - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - imunossupressores - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. o tratamento de graves, ativa e progressiva, a artrite reumatóide em adultos não previamente tratados com metotrexato. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita reduz a taxa de progressão do dano articular, como medido por raio-x e melhora a função física, quando administrado em combinação com metotrexato. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita pode ser administrado como monoterapia em caso de intolerância ao metotrexato ou quando a continuidade do tratamento com metotrexato é inadequada (para a eficácia em monoterapia consulte a secção 5. adalimumab não foi estudado em pacientes com idade inferior a 2 anos. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita reduz a taxa de progressão das lesões das articulações periféricas, conforme medido pelo raio-x em pacientes com poliarticular simétrica subtipos da doença (consulte a secção 5. 1) e melhora a função física. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 e 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

União Europeia - português - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hemoglobinúria, paroxística - imunossupressores - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidência de benefício clínico é demonstrado em pacientes com hemólise com sintoma clínico(s) indicativo de alta atividade de doença, independentemente de transfusão de história (consulte a secção 5.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

amgen biotecnologia do brasil ltda. - adalimumabe - antinflamatorios antireumaticos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

amgen biotecnologia do brasil ltda. - alfadarbepoetina - antianemicos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

amgen biotecnologia do brasil ltda. - blinatumomabe - antineoplasico

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

amgen biotecnologia do brasil ltda. - filgrastim - outros produtos que atuam no sangue e hematopoiese

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

amgen biotecnologia do brasil ltda. - cloridrato de cinacalcete - antiparatireoideanos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

amgen biotecnologia do brasil ltda. - pegfilgrastim - outros produtos que atuam no sangue e hematopoiese

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

amgen biotecnologia do brasil ltda. - denosumabe - outros produtos com acao no sistema musculo esqueletico